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Zalc et al. show that Pax3/7 transcription
factors regulate craniofacial development
through signaling mediated by the Aryl
hydrocarbon receptor (AHR), the receptor
for 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Pax3/7 interaction with AHR signaling
controls cell-cycle progression of cranial
neural crest cells and restricts the impact
of environmental stress signaling during
craniofacial development.
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Exposure to environmental teratogenic pollutant
leads to severe birth defects. However, the biological
eventsunderlying thesedevelopmental abnormalities
remain undefined. Here, we report a molecular link
between an environmental stress response pathway
and key developmental genes during craniofacial
development. Strikingly, mutant mice with impaired
Pax3/7 function display severe craniofacial defects.
We show that these are associated with an upregula-
tion of the signaling pathway mediated by the Aryl
hydrocarbon receptor (AHR), the receptor to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), revealing a ge-
netic interaction between Pax3 and AHR signaling.
ActivationofAHRsignaling inPax3-deficientembryos
drives facial mesenchymal cells out of the cell cycle
through the upregulation of p21 expression. Accord-
ingly, inhibiting AHR activity rescues the cycling
status of these cells and the facial closure of Pax3/7
mutants. Together, our findings demonstrate that
the regulation of AHR signaling by Pax3/7 is required
to protect against TCDD/AHR-mediated teratogen-
esis during craniofacial development.
INTRODUCTION
Exposure to environmental teratogenic pollutants is a major
threat to embryonic development. In humans, among the popu-
lation presenting birth defects, about 10%–15% of these anom-
alies are due to exposure of pregnant women to environmental
teratogenic pollutants (Gilbert-Barness, 2010). Among these
developmental defects, craniofacial malformations represent a
third of the defects observed (Dixon et al., 2011). It is postulated
that most teratogens interfere with genetic programs regulating
developmental processes (Dixon et al., 2011). Among environ-
mental pollutants, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
commonly known as dioxin, is a recognized potent teratogen
(Yonemoto, 2000). During historical events such as the American
Vietnam War or the Seveso incident, populations were exposed56 Developmental Cell 33, 56–66, April 6, 2015 ª2015 Elsevier Inc.to high doses of TCDD (Mocarelli, 2001; Stellman et al., 2003). It
was suggested that the spreading of TCDD led to an increase in
congenital defects, but rigorous epidemiologic study establish-
ing the link with TCDD exposure are lacking. Nevertheless,
TCDD exposure has been associated with developmental alter-
ations, including impaired psychomotor functions and cognition,
as well as reproductive and developmental defects (White and
Birnbaum, 2009). Furthermore, mouse embryos exposed to
TCDD present with hydronephrosis, thymic hypoplasia, cranio-
facial defects such as cleft palate, reduced weight, and lethality
at high doses (Courtney and Moore, 1971; King-Heiden et al.,
2012; Kransler et al., 2007; Moore et al., 1973; Pratt et al.,
1984; Yamada et al., 2006; Yonemoto, 2000).
The aryl hydrocarbon receptor (AHR) has been identified as the
receptor to TCDD (Fernandez-Salguero et al., 1996; Hankinson,
1995), suggesting this signaling pathway could be involved in
TCDD-mediated teratogenesis. While the etiology of TCDD-
induceddevelopmental defects remains unclear and studies link-
ing TCDD exposure and oral cleft in human are lacking, palatal
shelves from human, rat, and mouse display similar response
to TCDD exposure in vitro (Abbott et al., 1999a), which suggests
that humanexposure to TCDDmaybeassociatedwith oral clefts.
In vertebrates, the face mainly derives from the neural crest
(NC), a transient structure that arises at the dorsal tip of the clos-
ing neural tube (Knecht and Bronner-Fraser, 2002). Cells from
the neuroepithelium undergo an epithelial-mesenchymal transi-
tion prior to migrating to various regions of the embryo. Depend-
ing on their location along the anterior-posterior axis, these cells
populate different structures and give rise to a large variety of cell
types (Le Douarin et al., 2004). In the most rostral part of the em-
bryo, cranial NC cells (CNCC)migrate ventro-laterally to colonize
facial prominences (Birgbauer et al., 1995; Lumsden et al., 1991;
Osumi-Yamashita et al., 1994; Serbedzija et al., 1992), where
they participate in the formation of craniofacial bones, cartilage,
connective tissue, neurons, and glial cells (Couly et al., 1993;
Dupin and Sommer, 2012; Knecht and Bronner-Fraser, 2002;
Ko¨ntges and Lumsden, 1996; Noden and Trainor, 2005). Cranio-
facial malformations are generally linked to anomalies in CNCC
development, part of them being due to teratogen exposure.
Despite the identification of gene regulatory networks (GRNs)
underpinning CNCC development (Betancur et al., 2010), little
is known about how environmental pollutants interfere with these
genetic networks during craniofacial development.
Figure 1. Pax3 and Pax7 Are Essential for
Facial Development
(A) Histological transverse sections across the
head regions of E11.5 Pax3GFP/+; Pax7LacZ/+,
Pax3GFP/GFP; Pax7LacZ/LacZ, and Pax3Pax3-ERD/GFP
embryos at two distinct levels of the nasal pro-
cess, as indicated by black lines in the embryo
scheme. Hematoxylin eosin (H/E); lateral nasal
process (LNP); medial nasal process (MNP); nasal
pit (NP); neuroepithelium (NE); olfactory epithelium
(OE); and eye (E). Scale bar, 500 mm.
(B) Bright field and GFP expression (top andmiddle
panels, facial views) of E13.5 embryosofPax3GFP/+;
Pax7LacZ/+, Pax3GFP/GFP; Pax7LacZ/LacZ, and
Pax3Pax3-ERD/GFP embryos. Arrowheads represent
normally formed nasal processes. White stars indi-
cate rudimentary nasal processes. Bottom panels
show histological transverse sections through the
nasal processes of these embryos, as indicated by
the black line in the embryo scheme. Black stars
indicate divided nasal septum. Scale bars, 500 mm.
(C) GFP expression in E9.5 Pax3GFP/+; Pax7LacZ/+,
Pax3GFP/GFP; Pax7LacZ/LacZ, and Pax3Pax3-ERD/GFP
embryos (lateral views). Arrowheads indicate
the CNCC migrating into the facial prominences.
Scale bar, 200 mm.Central to these GRNs are genes coding for the paralogous
paired-box transcription factors PAX3 and PAX7. These tran-
scriptional regulators play a key role in the integration of inputs
during NC induction and in controlling the specification of NCde-
rivatives (Basch et al., 2006; Betancur et al., 2010; Minchin and
Hughes, 2008; Monsoro-Burq et al., 2005; Sato et al., 2005).
Although Pax3 and Pax7 function during early NC development
is highly conserved among vertebrates (Betancur et al., 2010),
their function during craniofacial formation is not understood.
Here, we show that mutant mice with impaired Pax3 and Pax7
function display severe facial morphogenesis defects. Using
a large-scale transcriptomic approach, we identified the AHR
signaling pathway as specifically upregulated during craniofacial
development of Pax3/7 deficient mice, leading to precocious
growth arrest in the cranial NC lineage. We further show that
blocking AHR signaling rescues facial growth and closure in
mice with impaired Pax3/7 function, while exposure to AHR
agonists such as TCDD leads to similar defects in embryosDevelopmental Cell 33, 5with reduced PAX3/7 activity, genetically
linking Pax3/7 with Ahr. Our data there-
fore demonstrate that important develop-
mental genes play a key function to
preserve the developing face from AHR/
TCDD-mediated teratogenesis.
RESULTS
Essential Role of Pax3 and Pax7
during Craniofacial Development
Using mouse genetic models, we first
examined the dynamics of Pax3 and
Pax7 expression profiles during craniofa-
cial development. As in other vertebrates(Nelms and Labosky, 2010), Pax3 expression is detected within
the anterior neural plate border prior to neural tube closure at
embryonic day (E)8.5 (Figure S1A). PAX3 expression co-localizes
with the NCC marker SOX9 (Nelms and Labosky, 2010; Fig-
ure S1B) and persists in several CNCC-derived tissues such as
the frontonasal mass (FNM) and the medial and lateral nasal pro-
cesses (MNP and LNP; Figure S1C). Of note, Pax7 expression is
restricted within Pax3 domain; first observed in the FNM and the
LNP, and later maintained in the LNP at E10.5 and E11.5 (Figures
S1C and S1D).
We next analyzed facial morphology in two distinct models
with altered PAX3 and PAX7 functions (Figures 1A and 1B). While
Pax3 is required for NC induction in the sacral, trunk, and
vagal regions (Li et al., 1999; Van Ho et al., 2011), cranial NC in-
duction occurs in our genetic models. However, a strong fronto-
nasal dysplasia phenotype with a fully penetrant frontal cleft was
observed in both Pax3GFP/GFP; Pax7LacZ/LacZ double mutant and
Pax3Pax3-ERD/GFP mutant embryos (Figures 1A, 1B, and S2A). In6–66, April 6, 2015 ª2015 Elsevier Inc. 57
Figure 2. Pax3Pax3-ERD/GFP Embryos Present a Fully Penetrant
Frontal Cleft Face Phenotype
(A) Immunostaining showing the expression of AP2a in red, PAX7 in white, and
GFP in green on transverse sections within the cranial regions ofPax3GFP/+ and
Pax3Pax3-ERD/GFP embryos at E9.5. Scale bar, 50 mm.
(B and C) Quantification of the proportion of AP2a+ (B) and SOX9+ (C) cells
within the PAX3+ population found on transverse sections through the cranial
regions of E9.5 PaxGFP/+ and Pax3Pax3-ERD/GFP embryos. Error bars represent
the SD.
(D) Percentage of Cleaved-CASPASE-3+ cells in the PAX3+ CNCC population
of E11.5 embryos of the indicated genotype. Error bars represent the SD.
(E) Whole mount in situ hybridization for Msx1 and Dlx2 transcripts on E11.5
embryos of the indicated genotype. Arrowhead indicates Dlx2 expression.
Star shows its absence. Dotted lines indicate nasal pit location. Lateral nasal
process (LNP), medial nasal process (MNP), maxillary process (Mx), and
mandibular process (Md). Scale bars, 500 mm.
(F) Composite images of multiple fields showing the oral cavity of DAPI stained
E15.5 embryos of the indicated genotype from which the lower jaw was
removed. White arrowheads indicate the remaining of the primary palate.
Black arrowheads indicate the bifurcated secondary palate. Maxillary process
(Mx), prominent rugae (pr), primary palate (pp), secondary palate (sp), site of
apposition and fusion of palatal shelves (saf), and primordia of vibrissae (v).
Scale bar, 500 mm.
58 Developmental Cell 33, 56–66, April 6, 2015 ª2015 Elsevier Inc.the latter, cells in the Pax3 positive lineage expressed a potent
dominant-negative form of Pax3 (Pax3-ERD), which alters both
PAX3 and PAX7 function (Bajard et al., 2006). This phenotype
contrasted with the medial fusion of the nasal processes
observed in wild-type (WT) embryos and other compound
Pax3/Pax7 mutants (Figure S2B), supporting the notion that
both proteins are required for facial development in mice. In
Pax3; Pax7 double mutant embryos, the phenotype was more
severe than in Pax3Pax3-ERD/GFP embryos, where the medial
and lateral nasal swellings were rudimentary and failed to fuse
resulting to a frontonasal cleft, whereas the maxillary and
mandibular prominences were less affected (Figures 1A, 1B,
and S2A). Histological analyses at E11.5 and E13.5 revealed
that the nasal process of both genetic models was severely
diminished and the nasal septum bifurcated (Figures 1A and 1B).
Since CNCC reached the facial prominences and early
specification is not affected in our genetic models (Figures 1C
and 2A–2C), we next assessed whether craniofacial defects
observed in Pax3Pax3-ERD/GFP and Pax3; Pax7 double mutant
embryos were due to increased cell death of CNCC. Strikingly,
we observed an increased proportion of apoptotic CNCC
when both Pax3 and Pax7 were missing (Figure 2D). Further-
more, we were unable to detect any cell co-expressing GFP
(PAX3) and b-galactosidase (PAX7) at E10.5 or E11.5 (data not
shown), suggesting that the PAX3+/PAX7+ cell population is
lost in double mutant embryos, precluding further analysis in
this genetic model.
In contrast, cell death was not increased in the CNCC of
Pax3Pax3-ERD/GFP embryos (Figure 2D). Thus, we tested whether
the frontal cleft face phenotype observed in Pax3Pax3-ERD/GFP
could be a consequence of tissue misspecification. We
observed impaired expression of Msx1 in the MNP and LNP
(Figure 2E) associated with reduced expression of Pax7 and
Pax9 in the LNP (Figure S3A), suggesting a proliferation defect
in the nasal processes of Pax3Pax3-ERD/GFP embryos (Bhatt
et al., 2013; Houzelstein et al., 1997; Nelms and Labosky,
2010). In addition, Dlx2 expression in nasal pits was barely
detectable (Figure 2E), implying patterning defects of the nasal
process in Pax3Pax3-ERD/GFP embryos (McKeown et al., 2005;
Thomas et al., 2000). As confirmed by skeletal staining at
E17.5, Pax3Pax3-ERD/GFP fetuses primarily presented with defects
in the premaxilla and the palate bones (Figure S3B). The primary
palate was almost completely absent, while the secondary pal-
ate was formed, but divided in two halves in Pax3Pax3-ERD/GFP
embryos (Figures 2F and S3B).
Collectively, these data demonstrate that Pax3 and Pax7
are essential in regulating morphogenesis, survival, patterning,
and specification of the frontonasal structures during facial
development.
Upregulation of AHR Signaling Pathway Expression Is
Associated with Impaired Pax3/7 Function
In order to gain insight into the molecular mechanism by which
Pax3 and Pax7 regulate craniofacial development, we performed
a microarray screen to compare the transcriptomes of the facial
prominences ofPax3Pax3-ERD/GFPmutant andPax3GFP/+ embryos
at E11.5 (Figure 3A). We identified 76 upregulated (Table S1) and
44 downregulated (Table S2) genes in cells with impaired Pax3/7
function compared to the control (Figure 3A). Among the
Figure 3. Impaired Pax3/7 Function Leads
to AHR Signaling Upregulation
(A) Volcano plot showing the 44 downregulated
(DR) genes (green) and 76 upregulated (UR) genes
(red) in GFP+ cells FACS-isolated from dissected
facial prominences of E11.5 Pax3Pax3-ERD/GFP
compared to Pax3GFP/+ control embryos. Blue
dots indicate the position of Ahr, Aldh1a3, and
Cdkn1a (p21) transcripts.
(B) Relative expression of Ahr, Aldhla3, and p21
assayed by RT-qPCR in cells FACS-sorted for
GFP from E11.5 embryos of the indicated geno-
type. Error bars represent the SD.
(C) Composite images of multiple fields showing
AHR expression in red and GFP in green on trans-
verse sections within the cranial regions of E11.5
embryos of the indicated genotype. Scale bars,
50 mm. Olfactory epithelium (OE), lateral nasal
process (LNP) and medial nasal process (MNP).
(D) Whole mount in situ hybridization for
Aldh1a3 and Fgf8 transcripts on Pax3Pax3-ERD/GFP
compared to Pax3GFP/+ control embryos. Stars
indicate increased area of transcripts expression
for Aldh1a3 or reduced expression for Fgf8. Scale
bar, 500 mm.
(E) Aldh1a3 and p21 relative expression assayed
by RT-qPCR in CNCC from E10.5 WT embryos,
exposed to TCDD or carrier as indicated. Error
bars represent the SD.deregulated genes, the most highly represented were compo-
nents of the AHR signaling pathway that were upregulated in
our screen, suggesting a strong activation of this signaling
pathway in Pax3Pax3-ERD/GFP embryos.
Transcripts levels for Ahr and its direct target genes, including
Aldh1a3, a gene coding for an enzyme involved in retinoic acid
production and nasal process development (Dupe´ et al., 2003;
Hankinson, 1995) and p21 (Cdkn1a, cyclin-dependent kinase
inhibitor 1A), a mediator of cell-cycle exit and growth arrest
(Barnes-Ellerbe et al., 2004; Besson et al., 2008), were higher
inPax3Pax3-ERD/GFPCNCC (Figure 3B). Consistently, we detected
a specific upregulation of AHR protein in the nasal process
mesenchyme and epithelium in both E10.5 and E11.5
Pax3Pax3-ERD/GFP embryos compared to control (Figures 3C
and S4). In situ hybridization for Aldh1a3 transcripts revealed
that its expression in the nasal process was shifted tomore ante-
rior andmedial positions within this tissue (Figure 3D), reinforcing
the notion that AHR signaling activity domain is increased when
the function of PAX3/7 is impaired. Furthermore, in the fronto-
nasal ectoderm, Aldh1a3 was previously shown to regulate
Fgf8 expression, a mediator of CNCC growth in the underlying
mesenchyme (Dupe´ et al., 2003; Hu et al., 2003). Consistent
with this, expression of Fgf8 was lost in the nasal epithelium ofDevelopmental Cell 33, 5Pax3Pax3-ERD/GFP embryos (Figure 3D),
suggesting a decreased proliferation of
the underlying mesenchymal CNCC that
could explain the smaller nasal promi-
nence phenotype. In addition, CNCC iso-
lated from facial prominences exposed
to TCDD, specifically induced Aldh1a3
and p21 expression (Figure 3E), demon-strating the responsiveness of AHR signaling to environmental
pollutants in this tissue.
Impaired Pax3/7 Function Leads to CNCCGrowth Arrest
and Frontal Cleft Face
Migration of the CNCC takes place in Pax3Pax3-ERD/GFP embryos
(Figure 1C), since the number of GFP+ cells was essentially
the same in Pax3Pax3-ERD/GFP and control embryos at E9.5
(Figure 4A). However, from E10.5 onward, the number of GFP+
cells within the frontonasal region was decreased by 30% in
Pax3Pax3-ERD/GFP embryos compared to control (Figure 4A).
Moreover, by E11.5 the proportion of GFP+ fluorescence-
activated cell sorting (FACS)-sorted cells over the total number
of cells was severely diminished by 34%, in Pax3Pax3-ERD/GFP
embryos compared to the control (Figures 4B and 4C). This
decrease in the PAX3+/PAX7+ population correlated with a
decline in the number of cycling cells in this population (Figures
4D and 4F), which explains the overall reduction of nasal process
size, leading to a frontal cleft face.
As we found a marked upregulation of the growth arrest
gene p21 in Pax3Pax3-ERD/GFP embryos, we hypothesized that
p21 induction might lead to growth failure of the nasal process,
resulting in the frontal cleft face phenotype. Immunostaining6–66, April 6, 2015 ª2015 Elsevier Inc. 59
Figure 4. Impairing Pax3/7 Function In-
duces Cell-Cycle Exit of CNCC
(A and B) Quantification of the number of PAX7+
cells within the GFP+ population on transverse
sections of the cranial structures of E9.5 and E10.5
embryos of the indicated genotype (B) GFP
expression in E11.5 embryos of the indicated
genotypes (lateral views). Scale bar, 500 mm. Red
boxes delineate the facial prominences dissected
to perform the FACS-sorting in (C). Error bars
represent the SD.
(C) Percentage of FACS-sorted GFP+ cells within
the total population of cells from the dissected
facial prominences of E11.5 embryos of the indi-
cated genotype. Error bars represent the SD.
(D and E) Phospho-HISTONE-3 (PH3) and p21
expression in red, PAX7 in white, and GFP in green
on transverse sections within the cranial regions
of embryos at indicated genotypes and stages.
Scale bars, 50 mm.
(F–I) Quantification of the proportion of PH3+ (F),
p21+ (G), AP2a+ (H), and SOX9+ (I) cells within the
PAX7+ population in sections through the cranial
regions of embryos with the stages and genotypes
indicated. Error bars represent the SD.for p21 and PAX7 demonstrated that 43% of the cells had
exited the cell cycle in Pax3Pax3-ERD/GFP embryos, while only
26% of the cells normally did so at E10.5 (Figures 4E and
4G). This increased cell-cycle exit was also seen at E11.5
(Figure 4G). In addition, this growth arrest was associated
with a decrease in the CNCC progenitor pool, as shown by
analysis of AP2a and SOX9 expression (Figures 4H and 4I).
Together these results suggest that during facial prominences
growth, upregulation of AHR signaling pathway in CNCC drives
these cells out of the cell cycle. Hence, this precocious cell-
cycle exit generates reduced craniofacial prominences unable
to fuse together, resulting in the formation of a frontal cleft
face.60 Developmental Cell 33, 56–66, April 6, 2015 ª2015 Elsevier Inc.Pax3/7-Mediated Regulation of
AHR Signaling Allows CNCC
Growth during Craniofacial
Development
In order to demonstrate that upregulation
of AHR signaling leads to the morpholog-
ical defects observed in Pax3Pax3-ERD/GFP
embryos, we treated control and mutant
embryos with a-naphthoflavone, an AHR
antagonist (Jang et al., 2007). Treatments
were performed by daily gavages admin-
istrated from E8.5 to E11.5. Strikingly,
a considerable proportion (39%) of
treated Pax3Pax3-ERD/GFP embryos ex-
hibited a rescue of the frontal cleft face
at E13.5 compared to the DMSO-
treated Pax3Pax3-ERD/GFP embryos, which
all display a frontal cleft face (Figures 5A
and 5C). Histological analysis of the
rescued embryos revealed that the nasal
septum was fused in its medial part (Fig-ure5A). Inaddition,weobserved thatAHR inhibitionwassufficient
to rescue primary palate formation (Figure 5B). Moreover, as the
alignmentof theprominent rugaesuggested, the fusionof thesec-
ondary palate appeared to be rescued, but delayed in time when
compared with DMSO-treated Pax3Pax3-ERD/GFP embryos, which
present with a bifurcated secondary palate (Figure 5B).
Following inhibition of AHR signaling with a-naphthoflavone,
the number of cycling PAX3+/PAX7+ cells in both control and
mutant embryos reached a similar level as in the DMSO-treated
Pax3GFP/+ control embryos (Figure 5D). Hence, inhibition of
AHR signaling in Pax3Pax3-ERD/GFP embryos was sufficient to
rescue the proportion of proliferating cells in the PAX3+/PAX7+
population.
Figure 5. Genetic Interaction between Pax3
and AHR Signaling Is Essential for Normal
Craniofacial Development
(A) Bright field and GFP expression of E13.5
embryos of the indicated genotype treated with
DMSO or a-naphthoflavone (facial views, top and
middle panels). Arrowheads indicate divided nasal
processes. Star marks its fusion. Bottom panels
represent composite images of multiple fields
showing histological transverse sections through
the nasal processes of these embryos. Arrow-
heads indicate divided nasal septum. Star marks
its fusion. Scale bars, 500 mm.
(B)Composite imagesofmultiple fields showing the
oral cavity of DAPI stained E15.5 embryos of the
indicated genotype treated with DMSO or a-naph-
thoflavone from which the lower jaw was removed.
White arrowheads indicate the remaining of
the primary palate. Black arrowheads indicate the
bifurcated secondary palate. Star marks the
alignment of the rugae in the secondary palate
of a-naphthoflavone-treated Pax3Pax3-ERD/GFP em-
bryos.Maxillary process (Mx), prominent rugae (pr),
primary palate (pp), secondary palate (sp), site of
apposition and fusion of palatal shelves (saf), and
primordia of vibrissae (v). Scale bar, 500 mm.
(C) Number of untreated, DMSO-, and a-naph-
thoflavone-treated Pax3Pax3-ERD/GFP embryos
presenting with a frontal cleft face or a closed
face with the stages indicated. At E11.5, for each
embryo, classification of the a-naphthoflavone-
treated Pax3Pax3-ERD/GFP embryos was based on
the nasal process fusion (not occurring in non-
rescued mutants) and the level of p21 expression
(upregulated in non-rescued mutants compare to
control embryos).
(D) Percentage of PH3+ cells within the PAX7+
CNCC population in E11.5 embryos of the indi-
cated genotype treated with DMSO or a-naph-
thoflavone. Error bars represent the SD.
(E) p21 relative expression assayed by RT-qPCR
in dissected faces of independent E11.5 embryos
of the indicated genotype treated with DMSO
or a-naphthoflavone. Dotted line represents p21
expression level in DMSO control embryos.To demonstrate that the rescue of the number of cycling
CNCC was due to the inhibition of AHR signaling, we quantified
the expression of p21 in these embryos. As anticipated, in nearly
half of a-naphthoflavone-treated Pax3Pax3-ERD/GFP embryos the
expression level of p21 within the facial prominences reached
similar levels compared to that observed in DMSO-treated
Pax3GFP/+ control embryos (Figure 5E), demonstrating that the
specific inhibition of AHR signaling was sufficient to rescue the
number of cycling CNCC in the facial prominences of these
embryos.
We also tested b-naphthoflavone, an AHR agonist (Swanson
andPerdew, 1993). Strikingly, nearly allb-naphthoflavone-treated
Pax3GFP/GFP or Pax3Pax3-ERD/GFP mutant embryos presented
with an early lethality by E13.5. By contrast, WT and Pax3GFP/+Developmental Cell 33, 5embryos all developed normally (data not
shown). The causeof deathwas not deter-
mined, but this further demonstrates astrong genetic link between Pax3/Pax7 and AHR signaling during
development.
Altogether, our results demonstrate that during facial morpho-
genesis PAX3 and PAX7 act by regulating CNCC growth through
the action of AHR signaling.
Pax3 and Pax7 Play a Safeguard Function against TCDD-
Induced Craniofacial Defects
To further establish the link between Pax3/7 function and AHR
signaling during craniofacial development, we speculated that
they act by restricting the input of AHR signaling to specific loca-
tions in the facial prominences. We therefore hypothesized that
reducing PAX3/7 activity in embryos exposed to TCDD should
lead to facial defects. Accordingly, we used TCDD to stimulate6–66, April 6, 2015 ª2015 Elsevier Inc. 61
Figure 6. PAX3 Plays a Safeguard Func-
tion against TCDD-Induced Craniofacial
Defects
(A) p21 relative expression assayed by RT-qPCR
in dissected faces of independent E11.5 embryos
of the indicated genotype treated with carrier or
TCDD. Dotted line represents p21 expression level
in carrier-treated control embryos.
(B) Bright field and GFP expression of E13.5 em-
bryos of the indicated genotype treated with car-
rier or TCDD (facial views, top and middle panels).
Arrowheads indicate divided nasal processes.
Scale bar, 500 mm.
(C) Number of carrier- and TCDD-treated E13.5
embryos presenting with a normal or a frontal cleft
with the genotype indicated.AHRsignaling in aPax3-null context. To this end,we intercrossed
Pax3GFP/+ mice and treated the pregnant females with a low
dose of TCDD. As expected, p21 expression was significantly
upregulated in both TCDD-treated Pax3GFP/+ and Pax3GFP/GFP
facial prominences (Figure 6A), confirming that AHR signaling
was activated. Importantly, WT and Pax3GFP/+ control embryos
were normally formed. Yet, while all vehicle-treated control
Pax3GFP/GFP mutant embryos displayed a normal craniofacial
phenotype, 56% of the TCDD-treated Pax3GFP/GFP mutant em-
bryos presented with a frontal cleft face phenotype (Figures 6B
and 6C). This phenotype is reminiscent to the one observed in
Pax3Pax3-ERD/GFP embryos (Figure 1B) and confirms that when
PAX3 function is impaired, activating AHR signaling is sufficient
to generate craniofacial defects.
Collectively, our results reveal an unexpected safeguard
function for PAX3/7 during face morphogenesis, whereby they
restrict AHR signaling input in order to allow the correct growth
and maintenance of CNCC during craniofacial development.
DISCUSSION
TCDD, andderivedcompounds suchaspolychlorodibenzo-p-di-
oxines (PCDDs) and polychlorodibenzofurane (PCDFs), are high-
ly toxic persistent chemicals released into the environment as un-62 Developmental Cell 33, 56–66, April 6, 2015 ª2015 Elsevier Inc.intentional by-products of incomplete
combustion of fossil fuels and wood,
and during the incineration of municipal
and industrial wastes. In humans, most
of the exposure occurs through food,
mainly meat and dairy products, fish,
and shellfish. The developing fetus is
especially sensitive to TCDD exposure. It
is therefore important to monitor the
in vivo cellular response to TCDD during
development in order to understand
and prevent the molecular and cellular
response following exposure to dioxins.
We show here that during morphogen-
esis of the face, PAX3 and PAX7 regu-
late the environmental stress response
pathway mediated by AHR signaling.
Restriction of AHR signaling by PAX3and PAX7 highlights a key function for this pathway in controlling
CNCC proliferation during craniofacial development.
Interestingly, inhibition of AHR signaling only rescues the
craniofacial phenotype of Pax3Pax3-ERD/GFP mutant embryos.
Severe defects in peripheral nervous system (PNS) and muscle
development are maintained in the trunk of these embryos
(Bajard et al., 2006; Van Ho et al., 2011). This suggests that
fundamental divergences exist between the GRNs controlling
cranial and trunk NC development, possibly due to the late
appearance of the head during evolution. Moreover, it points
out that the regulation of AHR signaling by Pax3may be a cranial
NC-specific feature. In the trunk,Pax3 has been shown to control
migration and early specification of NCC generating the PNS
(Tremblay et al., 1995; Van Ho et al., 2011). In the head, our
data demonstrate that Pax3 is mainly involved in regulating
the cell-cycle progression of CNCC via the regulation of AHR
signaling. This probably reflects the wider range of derivatives
that CNCCnormally generate compared to trunk NCC.Our study
has been mainly focusing on mesenchymal cells, however, anal-
ysis of cranial PNS development in Pax3Pax3-ERD/GFPmutant em-
bryos would further confirm or refute the divergence between
trunk and cranial GRNs governing NCC development.
In addition, the study of our mouse mutants for Pax3 and Pax7
revealed that one copy of either of these two genes is sufficient
to allow correct craniofacial development, demonstrating a
strong functional conservation (Figure S2B). Interestingly, in
Pax3Pax7/Pax7embryos, migration of NC cells is not affected (Re-
laix et al., 2004). This can suggest that Pax3 and Pax7 functions
are notably redundant during CNCC development or, alterna-
tively, it can also reflect that GRNs controlling formation of the
face are more robust than the ones controlling muscle develop-
ment. The latter hypothesis seems more plausible when looking
at the complexity of the GRNs controlling each different step of
CNCC development (Betancur et al., 2010), with several tran-
scription factors being described to be binding to the same
target gene to ensure its correct expression during the different
processes of craniofacial development.
In chick and Xenopus, Pax3 and Pax7 have been described
as essential factors for the induction and formation of the NC
(Basch et al., 2006; Monsoro-Burq et al., 2005; Sato et al.,
2005). However, in our mouse genetic models, despite the
absence of Pax3/7 or when their function is impaired, we
observed normal NC induction and migration in the facial prom-
inences of the embryo (Figure 1C). Whether this observation re-
flects a change inPax3/7 function during evolution, and how they
became associated with AHR latter during development remains
an open question. Our data reveal that unlike chick and Xenopus,
mouse Pax3/7 are not essential during early NC development,
but are involved in late craniofacial development to control the
maintenance of a cycling CNCC population. It is plausible that
the association with AhR signaling, which only starts to be signif-
icantly expressed from E10.5 (Abbott et al., 1995; Jain et al.,
1998), was co-opted during evolution as a mechanism to control
cell cycle of CNCC derivatives. It is believed that the AHR protein
evolved about 450 million years ago (Hankinson, 1995). Despite
pre-existing natural sources of TCDD, a marked increase in
environmental TCDD release occurred in the 19th century and
still persist today due to anthropogenic causes (Weber et al.,
2008). Thus, it is tempting to speculate that AHR signaling has
acquired different functions during evolution. The ability of
AHR to bind TCDD has made it a crucial regulator of pollution-
induced teratogenesis.
In the facial prominences of thedevelopingmouseembryo,Ahr
expression is detected from E10.5 (Abbott et al., 1995; Jain et al.,
1998), suggesting a potential role during early craniofacial devel-
opment. Yet, Ahr-null mouse mutants that are non-sensitive to
TCDD exposure (Fernandez-Salguero et al., 1996; Mimura
et al., 1997) do not showcraniofacial defects, but present defects
in liver and immune system development (Fernandez-Salguero
et al., 1995). Moreover, AhR is involved in the maintenance of
hematopoeitic stem cells quiescence (Singh et al., 2011). Studies
demonstrating the teratogenic effect of TCDD on mouse palate
development (Abbott et al., 1994, 1998, 1999b; Courtney and
Moore, 1971; Moore et al., 1973; Pratt et al., 1984; Yamada
et al., 2006; Yonemoto, 2000) are consistent with our observation
that AHR signaling upregulation is associated with the occur-
rence of craniofacial defects. During normal development, it
was shown that AHR is involved during secondary palate devel-
opment and is controlled by the retinoic acid (RA) signaling
pathway (Jacobs et al., 2011). Mutant mice missing components
of the RA signaling downregulate Ahr expression and do not
present with secondary palate clefts when exposed to TCDD
(Jacobs et al., 2011). Additional studies performed in zebrafishreported that TCDD-induced craniofacial defects are mediated
by AHR signaling. However, the defects are uniquely found in
the lower jaw, affecting the structure of the mandible and the
development of the Meckel’s cartilage (Keller et al., 2008; Plan-
chart and Mattingly, 2010), highlighting possible evolutionary
divergences between zebrafish and mammals.
TCDD-mediated activation of AHR signaling in a Pax3-null
context is sufficient to trigger craniofacial defects, confirming a
tight regulatory interaction between PAX3/7 function and AHR
signaling to control growth of facial prominences in mouse.
Accordingly, it was shown that AHR directly binds the first intron
of p21 in vitro (Barnes-Ellerbe et al., 2004; Dere et al., 2011;
Lo and Matthews, 2012). Importantly, despite p21 expression
being upregulated, all TCDD-treated Pax3GFP/+ embryos devel-
oped normally, suggesting that additional GRNs downstream
of PAX3 are also regulating craniofacial development. This will
be investigated in future studies.
Altogether, our data show that during craniofacial develop-
ment, Pax3 and Pax7 regulate AHR signaling expression and ac-
tivity. Restriction of AHR signaling by Pax3 and Pax7 highlights a
previously unknown key function for this pathway in controlling
CNCC proliferation during craniofacial development.
EXPERIMENTAL PROCEDURES
Mutant Mice for Pax3 and Pax7 and Reagents
The mutant alleles for Pax3 (Pax3nLacZ, Pax3GFP, and Pax3Pax3-ERD) and for
Pax7 (Pax7LacZ) have been described previously (Bajard et al., 2006; Mansouri
et al., 1996; Relaix et al., 2003, 2005). Of note, the Pax3Pax3-ERD allele is a con-
ditional one that drives the expression of the dominant-negative form of Pax3
(Pax3-ERD) composed of the Pax3 DNA binding domain fused to the engrailed
repressor domain (ERD) upon activation of a Cre recombinase. In this study,
the Cre was driven by the zygote specific PGK enhancer (Lallemand et al.,
1998). a-naphthoflavone and b-naphthoflavone (Sigma-Aldrich) were dis-
solved in DMSO then diluted in 1% carboxymethylcellulose (Sigma-Aldrich).
a-naphthoflavone (7.5 milligram per kilogram (mg/kg/day) and b-naphthofla-
vone (30 mg/kg/day) were then administered daily, orally to pregnant female
mice from E8.5 until E11.5. TCDD dissolved in toluene (Sigma-Aldrich) was
diluted in corn oil (Sigma-Aldrich). TCDD (4 mg/kg/day) was then injected
intra-peritoneally, to pregnant female mice from E8.5 until E11.5. All experi-
ments were conducted according to the Institutional Animal Care and Use
Committee of Paris 6 University.
Immunofluorescence and Quantification
Mouse embryos from timed pregnant females were fixed by immersion in 4%
paraformaldehyde/PBS for 45min to 2 hr at 4C. Fixed embryos were cryopro-
tected by equilibration in 30%sucrose/PBS, cryosectioned, and processed for
immunostaining as described in (Relaix et al., 2005). The following primary an-
tibodies were used, mouse anti-AHR (Abcam, 1:100), rabbit anti-AP2a (Santa
Cruz, 1:200), rabbit anti-Cleaved-CASPASE-3 (Cell Signaling, 1:100), mouse
anti-PAX7 (Developmental Studies Hybridoma Bank, 1:100), rabbit anti-Phos-
pho-HISTONE-3 (Millipore, 1:500), rabbit anti-p21 (Proteintech, 1:50), and goat
anti-SOX9 (R&D Systems, 1:100). Secondary antibodies DyLight 649 donkey
anti-mouse IgG (H&L), DyLight 649 donkey anti-rabbit IgG (H&L), and
DyLight 649 goat anti-rabbit IgG (H&L) were purchased from Jackson
ImmunoResearch and Alexa 594 goat anti-mouse IgG (H&L), Alexa 594 donkey
anti-goat IgG (H&L), andAlexa 594goat anti-rabbit IgG (H&L) fromLife Technol-
ogies. Analysis was carried out using a Leica TCS SPE confocal microscope
and images processedwith AdobePhotoshopCS4 software (AdobeSystems).
Cells were counted using ImageJ (version 1.46; NIH) and Cell Counter plugin
(Kurt De Vos, University of Sheffield, Academic Neurology) and were used to
calculate the percentage of one cell population against another. Mean ± SD
was given. The single (*), double (**), and triple (***) asterisks represent p values,
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non-parametric statistical test. All experiments have been performed on at
least three independent embryos for each condition.
Histology, X-Gal, and DAPI Staining, Skeletal Preparation, and
mRNA In Situ Hybridization
For histology, sections of embryos prepared as for immunofluorescence were
stained with hematoxylin and eosin (Vandenberg and Sassoon, 2009). X-Gal
staining and whole mount in situ hybridization were performed as previously
reported (Van Ho et al., 2011). For whole mount DAPI staining, protocol
described by Sandell et al. (2012) was used. Briefly, E15.5 embryos were fixed
for 2 hr in 4%paraformaldehyde/PBS andwashed three timeswith PBS before
incubation with 6 mg/ml DAPI in PBS overnight at 4C. After three washes with
PBS, embryos were placed under a fully automatized Nikon Ti microscope and
pictures were taken every 3 mm in the z-axis to cover all the embryo thickness.
The maximum projection of all the z-axis images using Fiji software revealed
the fine topological details of the embryos. Staining of bones and cartilages
of whole E17.5 embryos was performed as described in Depew et al. (2002).
For in situ hybridization, probes against the following mRNAs were used,
Dlx2 (Genbank, BC094317), Fgf8 (kindly provided by Martin G.), Msx1
(Genbank, BC016426), and Pax9 (Genbank, BC005794). Analysis was carried
out using a Leica MZ16 F stereomicroscope. Images were processed with
Adobe Photoshop CS4 software (Adobe Systems). Analyses were performed
on nR 3 embryos.
FACS Sorting, Cell Culture, and TCDD Treatment
For FACS-sorting, CNCC were isolated from faces of E11.5 embryos initially
incubated in digestion buffer, DMEM (Life Technologies), 0.1% trypsin, and
0.1% Collagenase D (Roche), and purified via FACS Aria II based on gating
of the GFP signal.
For TCDD treatment, CNCC were isolated from faces of E10.5 embryos,
incubated in digestion buffer, and purified using cell strainers (100 mm then
40 mm,BD Falcon) to obtain a single cell preparation. CNCCwere then cultured
in DMEM/F12 (1:1) medium for 24 hr with TCDD (100 nanomolar) or carrier in a
collagen-plated dish.
RNA Extraction, Microarray, and RT-qPCR
RNA was extracted directly from dissected facial prominences or from FACS-
sorted GFP+ cells from facial prominences using NucleoSpin RNA II Extract kit
(Macherey-Nagel), and the quality assessed with a NanoDrop ND-1000
(Thermo Scientific). cDNA was synthesized using the Transcriptor First Strand
cDNA Synthesis Kit (Roche).
Microarrays were performed using Affymetrix GeneChip MOE 130 2.0
(PartnerChip) chips containing 45,000 oligonucleotide probes (25 length of
the oligonucleotide) covering the totality of the 30,000 genes of the mouse
genome. Briefly, two-cycle cDNA synthesis was performed using 100 nano-
gram of total RNA. cDNA was then hybridized to GeneChip Mouse Genome
Array. Microarray analysis was performed usingGeneChip Operating Software
1.4. For statistical analysis, data from three biological replicates of each geno-
type were averaged then normalized using the Affymetrix Mas5.0 algorithm.
Statistical analysis was performed using Bioconductor software (http://www.
bioconductor.org/). Gene expression comparison between Pax3Pax3-ERD/GFP
and Pax3GFP/+ samples was performed using a statistical Student’s t test on
normalized data. Microarray data are available in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-3238.
RT-quantitative (q)PCR reactions were carried out in triplicate using the
LightCycler 480 System (Roche). The expression of each gene was normalized
to that of Gapdh transcripts. Results are given as mean ± SD. The single (*),
double (**), and triple (***) asterisks represent the p values, p < 0.05,
p < 0.005, and p < 0.0001, respectively for Student’s unpaired t tests. In Fig-
ure 4C, a–naphthoflavone treated Pax3Pax3-ERD/GFP embryos can be statisti-
cally segregated into two populations using a Ki2 test. We compared the
expression value for a given gene obtained in each a–naphthoflavone treated
Pax3Pax3-ERD/GFP embryo to the mean of the expression values for all the
DMSO treated Pax3GFP/+ embryos (control set). If there were significant
differences between these two values, the embryo was classified into the
population described as responsive to the a–naphthoflavone treatment, if
not the embryo was associated with the non-responsive population.
The following oligonucleotides were used:64 Developmental Cell 33, 56–66, April 6, 2015 ª2015 Elsevier Inc.Ahr, (forward [fwd]) TTCCAGGTTCTCAGGCATTC; (reverse [rev]) TGGGA
GCTACAGGAATCCAC
Aldh1a3, (fwd) GCAGCAGTGTTCACCAAAAA; (rev) CCTCAGGGGTTCTT
CTCCTC
p21, (fwd) GTACTTCCTCTGCCCTGCTG; (rev) GGGCACTTCAGGGTTT
TCTC
Gapdh, (fwd) CATGTTCCAGTATGACTCCACTC; (rev) GGCCTCACCCC
ATTTGATGT
ACCESSION NUMBERS
Microarray data were deposited on the Array Express database under the
number E-MTAB-3238.
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